Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Related Clinical Trial
Propranolol and Von Hippel-Lindau Disease Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Assessment of Residual VHL Function in Tumors – Can it Predict the Patients’ Individual Course of Disease? Phase II Study of Vandetanib in Individuals With Kidney Cancer A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma Drivers of Hypoxia-induced Angiogenesis in Tumor Development Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors MyVHL: Patient Natural History Study Metabolic Mapping to Measure Retinal Metabolism Use of Tracking Devices to Locate Abnormalities During Invasive Procedures National Eye Institute Biorepository for Retinal Diseases Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Pazopanib in Von Hippel-Lindau (VHL) Syndrome 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Von Hippel-Lindau Disease Genetic Epidemiology Study Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 TKI 258 in Von Hippel-Lindau Syndrome (VHL) Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

Brief Title

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Official Title

Double-Center Cross-Sectional Study of Contrast-Enhanced Ultrasound With Lumason/Definity as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Brief Summary

      The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal
      features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as
      conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)

Detailed Description

      This is a pilot cross-sectional study that compares contrast enhanced ultrasound to
      conventional ultrasound and contrasted MRI. Any patient undergoing annual imaging screening
      is eligible, but the investigators will target inclusion of at least 10 subjects who have at
      least 1 kidney lesion. Therefore, up to 5 subjects may have no current kidney lesions.
      Subject participation will be only for the day of CEUS study. There will be no follow-up
      period for this study. However, if results are encouraging, a longitudinal observational
      study may follow, and these same subjects would be eligible for enrollment. Eligible subjects
      will undergo a contrast enhanced ultrasound.

      Following completion of imaging, all CEUS, MRI (within 4 months) and B-mode (at time of CEUS)
      US studies will be de-identified. Blinded radiologists will interpret images and provide an
      overall assessment of risk of malignancy to each kidney using the Bosniak criteria for each
      kidney lesion present. The Bosniak criteria places cystic lesions into one of 5 categories
      (I, II, IIF, III and IV) based on lesion characteristics. CEUS based diagnosis will be
      compared to the diagnoses on routine B-mode US and contrast-enhanced MRI.

Study Phase

Phase 2

Study Type


Primary Outcome

Change in Radiologist's Lesion Evaluation compared to B-mode Ultrasound (percent)

Secondary Outcome

 Change in Radiologist's Lesion Evaluation compared to contrasted MRI (percent)


Von-Hippel Lindau


Perflutren lipid microsphere

Study Arms / Comparison Groups

 Perflutren Lipid Microsphere or Lumason
Description:  Patients with Von-Hippel Lindau disease will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 23, 2019

Completion Date

March 2024

Primary Completion Date

March 2024

Eligibility Criteria

        Inclusion Criteria:

        To be eligible for the present study, patients must meet the following criteria:

          1. Able to provide written informed consent

          2. Willing to comply with protocol requirements

          3. At least 16 years of age

          4. Carry a diagnosis of VHL and able to undergo routine clinical screening tests for RCC

        Exclusion Criteria:

          1. Critically ill or medically unstable or in an intensive care setting and whose
             critical course during the observation period would be unpredictable

          2. Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid
             (Definity®) or sulfur hexafluoride (Lumason®)

          3. Right to left shunt, severe pulmonary hypertension (Pulmonary artery pressure
             >90mmHg), or adult respiratory distress syndrome

          4. Active cardiac disease including any of the following:

             A. Severe congestive heart failure (class IV in accordance with the classification of
             the New York Heart Association) B.Unstable angina. C.Symptomatic arrhythmia (i.e.
             tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation,
             ventricular tachycardia, atrial flutter or fibrillation).

             D.Myocardial infarction within 14 days prior to the date of proposed microbubble

          5. Has any other medical condition or other circumstances that would significantly
             decrease the chances of obtaining reliable data or of achieving the study objectives
             such as:

               -  Mental illness

               -  Drug abuse

          6. Female patient who is pregnant or lactating

          7. Obesity that limits obtainment of acceptable images




16 Years - 99 Years

Accepts Healthy Volunteers



Emily Chang, MD, 919-966-3262, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

UNC Lineberger Comprehensive Cancer Center


 Lantheus Medical Imaging

Study Sponsor

Emily Chang, MD, Principal Investigator, University of North Carolina, Chapel Hill

Verification Date

August 2022